Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$19.67 USD

19.67
4,324,041

+0.84 (4.46%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $19.68 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Adma Biologics (ADMA) Stock Moves -1.31%: What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) concluded the recent trading session at $13.58, signifying a -1.31% move from its prior day's close.

What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?

by Zacks Equity Research

On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

Adma Biologics (ADMA) reachead $13.05 at the closing of the latest trading day, reflecting a -1.81% change compared to its last close.

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYC

Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics

by Zacks Equity Research

ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Wall Street Rally

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYC

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

by Zacks Equity Research

Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.

Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Adma Biologics (ADMA) reachead $11.64 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.

Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYX

Implied Volatility Surging for ADMA Biologics (ADMA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

Adma Biologics (ADMA) concluded the recent trading session at $10.84, signifying a -1.54% move from its prior day's close.

Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $10.71, indicating a +0.85% shift from the previous trading day.

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks.com featured highlights ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic Education

by Zacks Equity Research

ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic Education have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap May's Rally

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, NTIC, AGS, MBIN, STRA.

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and ResMed (RMD) have performed compared to their sector so far this year.

Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 60% and 6.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Adma Biologics (ADMA) reachead $6.74 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?

by Zacks Equity Research

On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

Santanu Roy headshot

Beat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus

by Santanu Roy

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.